Fusion Pharmaceuticals Q3 EPS $(0.25) Beats $(0.40) Estimate, Sales $2.01M May Not Be Comparable To $110.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Fusion Pharmaceuticals reported Q3 losses of $(0.25) per share, beating the analyst consensus estimate of $(0.40) by 37.5%. This is a 54.55% increase over losses from the same period last year. The company also reported quarterly sales of $2.01 million, beating the analyst consensus estimate of $110.00 thousand by 1.72K percent, a 1.11K percent increase over sales from the same period last year.

November 07, 2023 | 12:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Fusion Pharmaceuticals reported better than expected Q3 earnings and sales, which could positively impact its stock price.
Fusion Pharmaceuticals reported Q3 earnings and sales that beat analyst estimates. This positive financial performance could lead to increased investor confidence and a potential rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100